assay
≥99%
SMILES string
CCN(CC)CCNC(=O)c1ccc(NC(=O)CC)cc1
InChI
1S/C16H25N3O2/c1-4-15(20)18-14-9-7-13(8-10-14)16(21)17-11-12-19(5-2)6-3/h7-10H,4-6,11-12H2,1-3H3,(H,17,21)(H,18,20)
InChI key
CTHPVGZIOICAFO-UHFFFAOYSA-N
法规信息
新产品
此项目有
[A new anti-arrhythmia drug. I. Study of the anti-arrhythmia effects of a new N-acyl derivative of procainamide in rabbits].
J Kusowska
Acta poloniae pharmaceutica, 45(4), 346-350 (1988-01-01)
J Kusowska
Acta poloniae pharmaceutica, 46(1), 90-97 (1989-01-01)
In the recent years a remarkable number of new antiarrhythmic drugs have been introduced, but their side effects limit the application. Procainamide (PA) and N-acetylprocainamide (Acekainide, NAPA) display many undesired side effects, too. It was assumed that N-propionyl-procainamide, having antiarrhythmic
J Kusowska et al.
Acta poloniae pharmaceutica, 46(2), 187-194 (1989-01-01)
Procainamide (PA) often applied in cases of ventricular arrhythmias causes numerous cardiac and extracardiac undesirable symptoms. Its active metabolite, N-acetylprocainamide (NAPA; Acecainide) is known to affect less noxiously the ventriculo-atrial conduction and the intraventricular++ conduction, and it does not impair